Thyme Care raises $125 million, doubles valuation
Thyme Care secured $125 million in a Series E that lifted its valuation above $2 billion and is creating a parent company, Thyme Companies, to launch businesses addressing gaps in oncology care. The round was led by Morgan Health and included Humana and CVS Health Ventures, plus AlleyCorp, HealthQuest Capital, and a16z Bio + Health. Launched in 2020 and ranked No. 18 on the 2026 CNBC Disruptor 50 list, Thyme Care serves more than 10.5 million people across all 50 U.S. states, manages over $7 billion in oncology spend, reported revenue above $125 million, and is now profitable.
Thyme Care formed Thyme Companies after Series E at over $2 billion
Context
The company launched in 2020 and scaled a virtual navigation platform for cancer patients. It recently closed a Series E and reorganized under a parent company. The new group plans to launch businesses on biosimilars and clinical trial…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked